The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.

Caglayan, DilekKocak, Mehmet ZahidGeredeli, CaglayanTatli, Ali MuratEryolmaz, Melek KarakurtGoksu, Sema SezginAraz, Murat2024-02-232024-02-2320220732-183X1527-7755https://hdl.handle.net/20.500.12452/17396Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK[Abstract Not Availabe]eninfo:eu-repo/semantics/closedAccess[Keyword Not Available]The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.Conference Object4016Q1WOS:000863680302544Q1